Prescott Group Capital Management L.L.C. Makes New Investment in LifeMD, Inc. $LFMD

Prescott Group Capital Management L.L.C. acquired a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 687,328 shares of the company’s stock, valued at approximately $2,344,000. Prescott Group Capital Management L.L.C. owned about 1.43% of LifeMD at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. Quarry LP bought a new stake in LifeMD during the third quarter worth approximately $52,000. King Wealth Management Group bought a new stake in LifeMD during the third quarter worth approximately $68,000. Legal & General Group Plc increased its stake in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after acquiring an additional 6,614 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in LifeMD during the second quarter worth approximately $153,000. 35.52% of the stock is owned by institutional investors.

LifeMD Stock Performance

LFMD opened at $4.26 on Thursday. The stock has a market cap of $206.03 million, a price-to-earnings ratio of 85.22 and a beta of 2.03. The stock’s 50 day moving average price is $4.14 and its 200-day moving average price is $3.82. LifeMD, Inc. has a one year low of $2.56 and a one year high of $15.84.

LifeMD (NASDAQ:LFMD) last released its earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The business had revenue of $50.16 million for the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. As a group, analysts predict that LifeMD, Inc. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Mizuho raised LifeMD from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. Loop Capital set a $10.00 target price on LifeMD in a research note on Thursday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of LifeMD in a research note on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.14.

LifeMD Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.